Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors LATHAM, N.Y. / Oct 13, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today... Read More

Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the prior year Continues to expect to be cash flow positive for the full fiscal year 2026 Raised full year FY 2026 guidance for net sales, Med Tech net sales growth, Adjusted EBITDA and Adjusted EPS LATHAM, N.Y. / Oct 02, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ:... Read More

LATHAM, N.Y. / Sep 18, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2,... Read More

LATHAM, N.Y. / Aug 06, 2025 / Business Wire / AngioDynamics, Inc . (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief... Read More

Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages LATHAM, N.Y. / Jul 28, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized... Read More

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM, N.Y. / Jul 23, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of... Read More

Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2 million of free cash flow in the quarter as a result of strong topline growth and operational efficiency efforts LATHAM, N.Y. / Jul 15, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and... Read More

LATHAM, N.Y. / Jul 07, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 before the market open on Tuesday, July 15,... Read More

Multi-center, multi-national study builds on existing U.S. PE Clearance and CE Mark to assess mechanical thrombectomy treatment and long-term functional outcomes in intermediate-risk PE patients across Europe LATHAM, N.Y. / Jun 23, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding... Read More

LATHAM, N.Y. / Apr 02, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter... Read More

LATHAM, N.Y. / Mar 31, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately... Read More

LATHAM, N.Y. / Mar 19, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2,... Read More

LATHAM, N.Y. / Mar 10, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief... Read More

Trial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases LATHAM, N.Y. / Jan 30, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized... Read More

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F18 85 System in pulmonary embolism treatment. LATHAM, N.Y. / Jan 13, 2025 / Business Wire / AngioDynamics, Inc . (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer... Read More

LATHAM, N.Y. / Dec 19, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8,... Read More

LATHAM, N.Y. / Dec 09, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The... Read More

Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention LATHAM, N.Y. / Oct 23, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and... Read More

New Codes Expand Market Access to Treatment with the NanoKnife ® System LATHAM, N.Y. / Oct 21, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT ® Category I codes for the... Read More

LATHAM, N.Y. / Oct 03, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter... Read More

Multi-center, multi-national study to evaluate mechanical thrombectomy treatment in acute, intermediate-risk PE patients in European Market LATHAM, N.Y. / Sep 19, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today... Read More

LATHAM, N.Y. / Sep 19, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3,... Read More

Regulatory approval enables entry of Auryon Atherectomy System in European market LATHAM, N.Y. / Sep 03, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the Auryon... Read More

LATHAM, N.Y. / Jul 29, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is scheduled to participate in the following upcoming investor conferences: 9 th Annual Needham Virtual... Read More

LATHAM, N.Y. / Jul 16, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter... Read More

LATHAM, N.Y. / Jul 08, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2024 before the market open on Tuesday, July 16,... Read More

Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market LATHAM, N.Y. / May 21, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the... Read More

New data finds AlphaVac F18 85 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden LATHAM, N.Y. / May 06, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding... Read More

Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support catheter products, to further streamline its product portfolio GAAP As Reported Pro Forma* Net Sales: $75.2 million $66.0 million Growth: N/A 8.0% Gross Margin 47.7% 51.1% GAAP Loss per... Read More

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios LATHAM, N.Y. / Apr 04, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States... Read More

LATHAM, N.Y. / Apr 01, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent... Read More

LATHAM, N.Y. / Mar 19, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4,... Read More

LATHAM, N.Y. / Mar 06, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial... Read More

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and Syntrax products LATHAM, N.Y. / Feb 15, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment... Read More

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient Recovery LATHAM, N.Y. / Jan 23, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life,... Read More

Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the prior-year quarter Med Tech net sales of $25.4 million increased 3.5% Med Device net sales of $53.7 million increased 2.3% on a pro-forma basis Gross margin of 50.9% declined 80 basis points on a pro-forma basis year over year GAAP loss per share of $0.72 and adjusted loss per share of $0.05 Cash and cash... Read More

LATHAM, N.Y. / Dec 21, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief... Read More

LATHAM, N.Y. / Dec 07, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January... Read More

122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-up LATHAM, N.Y. / Dec 07, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary... Read More

Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales Net sales increased 5.7% on a pro-forma basis when excluding Dialysis and BioSentry, compared to the prior-year quarter Med Tech net sales of $25.9 million increased 13.3% Med Device net sales of $52.8 million as reported Med Device net sales increased 2.3% on a... Read More

LATHAM, N.Y. / Sep 12, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market open on Wednesday, October... Read More

Pivotal Milestone Accelerates Pathway to Specific Indication LATHAM, N.Y. / Aug 15, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted... Read More

Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population LATHAM, N.Y. / Aug 03, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced the completion... Read More

LATHAM, N.Y. / Jul 31, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief... Read More

LATHAM, N.Y. / Jul 24, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company’s Board of Directors. Ms. Burgess brings over 35 years of management,... Read More

Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 250 basis points year over year GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction... Read More

LATHAM, N.Y. / Jun 20, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2023 before the market open on Wednesday, July... Read More

Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million LATHAM, N.Y. / Jun 08, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it has completed the sale... Read More

LATHAM, N.Y. / Apr 11, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief... Read More

Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 200 basis points year over year GAAP loss per share of $0.24 and adjusted loss per share of $0.03 LATHAM, N.Y. / Mar 30, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ:... Read More

LATHAM, N.Y. / Mar 13, 2023 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March... Read More

Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% increased 100 basis points year over year GAAP loss per share of $0.21 and adjusted earnings per share of $0.01 AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative... Read More

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 41... Read More